Full Press Release Details
12 Months Activities & Milestones for 2018
milestones in the next 12 months include:
TIKVA, Israel, January 11, 2018 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing
a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its near-term
milestones for 2018 including events related to the rheumatoid arthritis/psoriasis drug Piclidenoson and the liver disease drug
Company believes that it is close to reaching certain significant clinical milestones in its efforts to bring the two lead drug
candidates, Piclidenoson and Namodenoson, to market. Both drug candidates are administered to patients orally in the form of a
tablet and have demonstrated an excellent safety profile in prior clinical trials. The below near-term key events provide an outlook
of Can-Fite's objectives and potential for increased growth.
expects that these pivotal Phase III studies will serve as the first of two pivotal studies required for European Medicines Agency
(EMA) drug approval.
are very excited at the opportunity of potentially receiving further validation of our drug candidates which represents significant
steps forward in our commitment to delivering treatments to patients. We hope to see this come to fruition upon conclusion of
our various trials." stated Can-Fite CEO Dr. Pnina Fishman.
Piclidenoson and Namodenoson, are focused on multi-billion dollar market opportunities. The rheumatoid arthritis and psoriasis
therapeutic market is dominated by biological drugs that are primarily administered via intravenous injection (IV) and have potential
side effects. Rheumatoid arthritis and psoriasis are huge unmet need markets, where rheumatoid arthritis is estimated to reach
$35B in 2020 and psoriasis is forecast to reach $9B in 2018.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multibillion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.
The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for rheumatoid arthritis and is expected
to enter a Phase III trial for psoriasis during 2018. Can-Fite's liver cancer drug, Namodenoson, is in Phase II trials for
hepatocellular carcinoma (HCC), the most common form of liver cancer, and for the treatment of non-alcoholic steatohepatitis (NASH).
Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment
for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers
including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment
of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the
treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical
studies to date. For more information please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations,
strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking
statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe,"
"expect," "intend," "plan," "may," "should" or "anticipate"
or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate
strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various
filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the
approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could
cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking
statements include, but are not limited to: the initiation, timing, progress and results of our preclinical studies, clinical
trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or
to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates,
and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of
our product candidates; our ability to establish and maintain corporate collaborations; the implementation of our business model
and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual
property rights of others; estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel
on our business; and risks and other risk factors detailed in Can-Fite's filings with the SEC and in its periodic filings
with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced
by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking
statements, whether as a result of new information, future events or otherwise.